Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic
  • Search Hotels in Walnut Creek Guide

  • ROOMS:

EAGLE PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. is Investigating Eagle Pharmaceuticals, Inc. on Behalf of Eagle Pharmaceuticals Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Dec. 10, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Eagle Pharmaceuticals, Inc. (“Eagle Pharmaceuticals” or the “Company”) (NASDAQ: EGRX) on behalf of Eagle Pharmaceuticals stockholders. Our investigation concerns whether Eagle Pharmaceuticals has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On November 9, 2023, Eagle issued a press release stating that “it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today . . . . The Company requires more time to review potential adjustments relating to the reporting of sales of PEMFEXY(R) prior to filing its Form 10-Q. In addition, the Company expects to revise its previously disclosed 2023 full year guidance downward.”

On this news, Eagle Pharmaceuticals' stock price fell $4.16 per share, or 30.36%, to close at $9.54 per share on November 9, 2023.

Then, on November 29, 2023, before the market opened, Eagle issued a press release stating “[e]ffective immediately Scott Tarriff, Founder, President and Chief Executive Officer of the Company, has announced his resignation and retirement from his positions with the Company as President, Chief Executive Officer and Director on the Company's Board of Directors.”

On this news, Eagle Pharmaceuticals' stock price fell $2.55 per share, or 30.98%, to close at $5.68 per share on November 29, 2023.

If you purchased or otherwise acquired Eagle Pharmaceuticals shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.